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Pharmacokinetics of antibiotics 
F1 MIC-Based Inter-Species Prediction of the 
Antimicrobial Effect: Ciprofloxacin against 
Different Bacteria in an In vitn, Dynamic Model 
S. Vosaov', A. Shevchenko', A. Firsov I ,  G. Cornagka'. 'Centre of 
science G. Technology LekBioTech, Moscw, Russia, 'Instifute 4 
Microbiology, University of VErona, Italy 
Objectives: To examine whether the antimicrobial effect (AME) of 
ciprofloxacin (CIP) on bacteria of one species is predictable by the 
AME on bacteria of another species. 
Methods: The kinetics of killing and regrowth of a c h c a l  iso- 
lates of S. aureus, E .  coli and Pamginosa (MICs = 0.6.0.013 and 0.15 
pg/ml, respectively) were studied with a series of in vitro simulated 
monoexponential pharmacokinetic profiles which mimicked single 
administration of CIP 
( T 1 , p  = 4 h) over a wide dose range. Initial concentrations of 
CIP were selected to provide AUC/MIC ratios, which varied over 
a 1000-fold range (8-8.160 p g / d  x h/ml). To accurately com- 
pare the pharmacodynamics of CIP, the duration of the observation 
periods was designed to provide thorough evaluation of bacterial 
regrowth. The AME was expressed by its intensity (IE - the area 
between the control and the bacterial killing/repwth curves). 
Results: CIP produced a distinct AUC/MIC-dependent AME as 
expressed by IE on the three mimorganisms. For the almost total 
AUC/MIC range, IE was directly proportional to log AUWMIC. 
There was no species Merences in the AME produced by the same 
AUC/MIC. For example, at AUCIMIC = 280 pg/ml x h/ml, the 
respective values of IE on S. a u m ,  E. coli and F? aeruginosa were 192, 
178 and 181 log CFU/ml x h. Moreover, the IE-log AUC/MIC 
plots for all three organisms were juxtaposed and fitted by the same 
linear regression (2 = 0.98). 
Conclusions: Thus, AUC/MIC-based prediction of the AME 
of CIP and, probably, other fluoroquinolones may be relevant to 
Merent bacterial species. 
ml Uptake and lntracellular Activity of Ofloxacin 
and its Isomers Levofloxacin and D-ofloxacin in 
Human Phagocytic and Non-phagocytic Cells 
1. Garcia, A. Pascual, S. Ballesta, EJ. Perea. Dept ofMicrobidoa, 
School of Medicine, Seville, Spain 
Objectives: To evaluate the penetration of ofloxacin and its isomers 
levofloxacin and D-ofloxacin into human polymorphonuclear leu- 
cocytes (PMN), human peritoneal macrophages (PMQ) and tissue 
culture epithelial cells (McCoy). The intracellular activity of these 
drugs in phagocytic cells was also assessed. 
Methods: The uptake of fluoroquinolones by human cells was 
evaluated by a fluorometric assay. Results are expressed as cellular 
to extracellular concentration ratios (WE). For intracellular activ- 
ity, phagocyhc cells containing intracellular bacteria were exposed to 
Merent extracellular concentrations of the drugs. After 3 h incuba- 
tion, cells were lysed and viable bacteria determined by plating and 
colony counting. 
Results The C/E values of the three fluoroquinolones were al- 
ways higher than 3.6 and 2.6 in PMN and PMQ, respectively (ex- 
tracellular concentration: 2, 5 and 10 =/l). The C/E ratios of 
the three fluoroquinolones for McCoy cells were lower than those 
in PMN but s t i l l  hgher than 2. The uptake of ofloxacin and its 
isomers by both phagocytic and non phagocytic cells was rapid, 
non-saturable and reversible. AU the fluoroquinolones (extracellular 
concentrations: 2, 5 and 10 mgA) produced a sigdicant reduction 
in viable intraphagocytlc Staphylococcuc uureus in phagocytic cells. 
Conclusions: Ofloxacin and its isomers levofloxacin and 
D-ofloxacin reach high intracellular concentrations in phagocyac 
and non-phagocytic cells while remaining active in the former. 
Penetration of Levofloxacin (HR355) into Lung 
Tissues after a Single 500 mg Oral Dose 
D. Honeybourne, J.M. Andrews, G. Jevons, N.P. Brenmrd, 
B. Cunningham, R. Wise. Departmentc of Thoracic Medicine and 
Medical Microbiolon, City Hospital, Dudley Road, Birmingham, UK 
Objectives: Levofloxacin is the L-isomer of the racemate ofloxacin. 
This study was designed to compare lev& of levofloxacin at potenhal 
sites of respiratory mfection, i.e. bronchial mucosa (BM), epithelial 
lining fluid (ELF) and alveolar macrophages (AM) with simultaneous 
serum levels measured at bronchoscopy. 
Methods: A total of 35 patients (24 male) undergoing dugnos- 
tic fibreoptic bronchoscopy were studied. Patients were excluded 
if there was evidence of active lung infection. A single 500 mg 
oral dose was given in one of 6 time periods before bronchoscopy. 
During bronchoscopy, lavage was carried out, mucosal biopsies per- 
formed and simultaneous serum was obtained. The lavage aspirate 
was immediately centrifuged and the supernatant keze-dried. The 
cell pellet and mucosal biopsies were ultmonicated. The samples 
were assayed using a validated microbiological technique. 
Results Mean serum, AM, ELF and BM levels at 0.5, 1, 2, 4, 
6-8 and 12-24 hours were: 0.5 h - 5.9 mg/L, 22.7 mg/L, 5.9 mg/L 
and 5.2 mg/Kg; 1 h - 6.6, 32.5, 10.8 and 8.3; 2 h - 4.9, 41.9, 
9.0, 6.5; 4 h - 4.1, 33.4, 10.9, 6.0; 6-8 h - 4.0, 46.9, 10.1, 4.8; 
12-24 h - 1.2 in serum, 16.2 in AM but levels in BM and ELF only 
measurable in 3 out of 6 patients. 
Conclusion: Levels of lev05oXacin at the lung sites exceeded the 
MIC90 values against common respiratory pathogens in all subjects 
in the first 5 time periods. 
I P378 I Serum Bactericidal Activii of Levofloxacin 
A. Wiedersich H.E Geerdes-Fenge I ,  M. Rau S. Wagner ', 
A. Bryskier ', H. Lode ' . 'Dept.  of Chedlnfea .  Diseasec, 'Dept. of 
Clinical Microbioloa, both City Hospifal Zhlendo~/Heckechorn, 141 09 
Berlin, Germany, ' H M R ,  Romainville, France 
New fluoroquinolones may become more important for clinical us- 
age in regards to the increasing resistance of Gram-negative bacteria. 
Objectives: Serum bactericidal activities of levofloxacin were in- 
vestigated in a single open dose study including 12 healthy female 
volunteers receiving 500 mg p. 0. 
Methods: The serum bactericidal activities were measured with 
the microdilution method according to the guidelines by the NCCLS 
against recently isolated saains of 5 Merent speaes of Entnobacfm'acae 
(E. coli, K .  pneumoniae, E. cloacae, C.jeundii ,  S.  mamcens)). 10 strains 
of each species were examined. Most of these strains were moderately 
or totally resistent against 3rd generation cephalosporines. 
Results Mean reciprocal bactericidal titers at 1, 2, 12 and 24 
hours after adrmnistration were determined 
I h  2 h  12h 24h 
E .  roh 217 210 58 14 
K. pncumonwe 50 45 14 6 
E. cloacae 47 49 19 7 
S. mammu 55 62 18 5 
c. J%und*i 150 117 50 14 
Conclusions: Levofloxacin offered an excellent serum bacteri- 
cidal activity and even after 24 h it was s t i l l  effective against these 
different nosocomial pathogens. 
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Joint Cartilage in Juvenile and Aged Rats After 
Feeding a Magnesium-Deficient Diet or 
Treatment with Ofloxacin 
R. Stahlmann I ,  C. Forster I ,  U. Zippel I ,  E. Lozo J. Vormann', 
M. Shakibaei ', HJ, Merker 3 .  'Depurtment of Clinical Pharmacology 
and Toxicology, 'Department ofMolecular Biology and Biochemistry, 
'Department of Anatomy, Universitiitsklinikum Benjamin Franklin, Free 
University, Berlin, Germany 
Objectives: Quinolones exhibit chondrotoxic effects in juvede 
anunals and thus are conuaindicated in juvenile patients. Little is 
known about the mechanism and the phase spechcity of this effect, 
but it might be relaced to the magnesium-chelating properties of the 
Methods: We studied knee joint cartilage &om juvenile and 
aged rats by light and electron microscopy as well as immunoh- 
tochemistry after (1) treatment with 5uoroquinolones (e. g. 600 mg 
05oxacin/kg b wt) and (2) after feeding a magnesium-deficient diet. 
Resdw. Characteristic cartilage lesions such as swollen ma- 
trix or clefts were found after treatment with ofloxacin and other 
quinolones. Identical lesions were found in 3-week-old rats or in 
4-week-old rats with dietarily induced magnesium deficiency (rats 
were fed the magnesium-deficient diet for 9 to 15 days). Lesions 
were not inducible by feeding the diet to 8-week-old rats. Aged 
rats (15 months) did not develop arthropathy after a 4-week treat- 
ment period with daily oral doses of 600 mg ofloxacin/kg b wt plus 
magnesium-deficient diet. 
Conclusions: Quinolone-induced arthropathy is probably caused 
by a deficit of functionally available magnesium in joint cartilage, due 
to the chelating properties of quinolones. The sensitive period for 
the chondrotoxic effect in rats is short. Aged rats are not sensitive. 
drugs. 
1 P380 1 Concentrations of Sparfloxacin and Ofloxacin in 
Plasma and Joint Cartilage from Juvenile Rats 
R. Schwabe I ,  K. Borner ', U. Zippel I ,  C. Forster I ,  
1. Baumann-Wilschke I ,  R. Stahlmann 
Pharmacology and Toxuology, Universitiitsklinikum Benjamin Franklin, 
Free Univmity, Berlin, Germany, 'Department .f Clinical Chemistry and 
Clinical Biochemist% Universitiitsklinikum Benjamin Franklin, Free 
Uniumity, Berlin, Germany 
Objectives: Analysis of quinolone concentrations in rat joint carti- 
kge to provide a basis for a reasonable extrapolation of toxicological 
data. 
Methods: Using an HPLC method we determined concentra- 
tions of spadoxacin (spa) and ofloxacin (ofl) in plasma and femoral 
head carblage h m  immature rats (5 weeks old) after oral treatment 
with single chondrotoxic doses (spa: 1800 mg/kg; ofl 1200 mg/kg) 
and a non-chondrotoxic dose (ofl: 300 mg/kg). 
Resdts: Cartilage lesions were detected in 5/8 rats (spa, 1800 
mg/kg), 4/4 rats (ofl, 1200 mg/kg) and 0/7 rats (ofl, 300 mg/kg) 
by light microscopy Peak plasma concentrations were obtained after 
180 and 45 min (spa: 19.1 f 1.7 mg/l; ofl 45.4 f 12.4 and 26.4 f 
13.4 mg/l). Ofl concentrations in cartilage after 1200 mg/kg were 
57.8 f 10.6; 55.3 f 13.3; 104.4 f 32.8; 114.8 f 17.2; 30.7 f 18.4 
mg/kg after 15, 45, 180, 360, and 720 min, respectively (mean f 
SD; n = 5 each group). Mean peak concentration after the low dose 
was 48 mg/kg. Spar5oxacin concentrations were in the same range 
as ofloxacin concentrations at chondrotoxic doses. 
Conclusions: Concentrations in joint d a g e  of >50 (to 100) 
mg ofloxacin or sparfIoxacin/kg tissue are associated with cardage 
lesions in juvenile rats after a single dose regimen. 
Study was supported by a grant &om Deutsche Forschungsge- 
meinschat? 
'Department of Clinical 
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Predictors of Antimicrobial Effect of 
Fluoroquinolones: Trovafloxacin vs. 
Ciprofloxacin against Escherichia coli in an In 
Vitro Dynamic Model 
A. Firsov', S. Vostrov', A. Shevchenko I ,  S .  Zinner'. 'Centre of 
Science G Technology LekBioTech, Moscow, Russia, 'Brown University, 
Providence, RI, USA 
Objectives: To exatnine various predictors of the antimicrobial ef- 
fect (AME) of trovafloxacin (TR) and cipro5oxacin (CI) as studied 
in an in vim dynamic model. 
Methods: The kinetics of killing and regrowth of a clinical isolate 
of E. coli (MICm = 0.25, MIC,cr = 0.12 pg/ml) were studied 
with a series of in vim simulated monoexponential pharmacokinetic 
profiles which mimicked q.d. TR (TI,' = 10 h) and b i d .  or q.d. 
CI (Tip = 4 h) administration. Each of three profiles were selected 
to provide s u n i l a r  AUCIMIC ratios, which, in turn, varied over 
an 8-fold m g e  (58-466 pgxh/ml). The AME was expressed by 
its intensity (IE - the area between the control and the bacterial 
lalling/regrowth curves). 
Results: Regardless of the dosing regimen and the drugs, an 
increase in AUC/MIC produced a greater AME that was directly 
proportional to log AUC/MIC. The AME of T R  was superior 
to b.i.d. CI, and especially, to q.d. CI. The slopes of the IE-log 
AUCIMIC and -log A U C c ~  (AUC above MIC) plots for TR and 
CI (b.i.d. or q.d.) were Werent (the highest slope was inherent 
in TR). Unlike log AUC/MIC and log AUC,a, the IE-T~E (time 
above MIC) plots for TR and CI (b.i.d. and q.d.) were juxtaposed 
and fitted by the same h e a r  regression (2 = 0.949). 
Conclusions: Thus, T& is the most reliable predictor of the 
efficacy of both T R  and CI. This i n h c t l y  reflects the decisive 
impact of the merence in their half-lives on the AME. 
P382 1 Trovafloxacin vs. Ciprofloxacin against Bacteria 
of Similar Susceptibility to Both Drugs: A Study 
with Pseudomonas aemginosa in an In Viro 
Dynamic Model 
A. Firsov I ,  S. Vostrov I ,  A. Shevchenko I ,  S. Zinner2. 'Centre .f 
Science G Technology LekBioTech, Moscow, Russia, 'Brown University, 
Providence, RI, USA 
Objectives: To demonstrate the impact of trova5oxacin's (TR) rel- 
ative to ciprofloxacin's (CI) pharmacokinetics on the antimicrobial 
effect (AME) as studied in an in vitro dynamic model. 
Methods: A clinical isolate of I? aemginosu (MICm = 0.3, MICcl 
= 0.15 pg/ml) was exposed to monoexponentially changing con- 
centrations of simulated q.d. TR (Tip = 10 h) and b.i.d. CI (TI/' 
= 4 h) administration, to provide similar values of the AUC/MIC 
that varied witlun the range of 58-466 pgxh/ml. The AME was 
expressed by its intensicy (IE - the area between the control and the 
bacterial killing/regrowth curves). 
Results: For both drugs an increase in AUC/MIC of T R  and CI 
produced a greater AME as expressed by IE. Moreover, linear rela- 
tions between 1, and log AUC/MIC were established for both drugs. 
The AME of TR was superior to C1, especially at hgh AUC/MlC 
since the slope of the IB-log AUCIMIC plot for TR was higher than 
that for CI. Based on these data, the respective dose (D) - response 
relations were reconstructed. using the IE-lOg D plots, AMEs pro- 
duced by daily doses of 300 mg TR and 1000 mg CI were 295 and 
240 log CFU/mlxh, respectively. The predicted daily dose of TR 
whch is equi-effective to the dose of CI was 201 mg. 
Conclusions: Thus, q.d. TR (300 mg) may be more efficient 
than b.i.d. CI (1000 mg) despite similar intrinsic activity. Moreover, 
acceptable efficacy may be provided by a lower T R  dose. 
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\ P383 I Food Does Not Affect the Bioavailability of 
Tmvafloxacin Tablets 
€2. Teng, L.C. Dogolo, J. Vincent, D.A. Schumacher, 
H.L. Friedman. Central Research Division, Dfizer Iru., Groton, C?; 
USA 
Trovafloxacin (CP-99, 219) is a new fluoroquinolone antibacterial 
agent with a broad spectrum of in oitro activity against Gram-positive 
and Gram-negative organisms, most notably streptococci such as 
Strpptococcus pneumoniae. To investigate the effect of food in the 
gastrointestinal tract on the bioavailability of trodoxacin, a ran- 
domized, open-label, two-way crossover study was conducted in 28 
healthy male and female volunteers, each of whom received two 
100-mg tablets either in a fasted state or after a standard breakfast. 
Blood was sampled at intervals for 48 h afcer study drug adrmnistra- 
don. The mean C, values of 1.9 and 2.0 pg/ml, T,, values of 3.4 
and 2.1 h, and AUC values of 25.6 and 24.8 fi-h/ml were observed 
under fed and fasted conditions, respectively. The mean terminal 
half-lives were similar under the two treatment conditions (9.4 vs 
9.6 h). The standard meal delayed T, by about 1 h, but had no 
effect on AUC and C,, The mean bioavailability of trodoxacin 
tablets under fed conditions relative to fasted conditions was 103.2%. 
The results indicate that a standard breakfast has no effect on the 
bioavailability of trovafloxacin when administered orally as tablets. 
I P384] Effects of Orally Administered Trovafloxacin on 
the Steady-State Pharmacokinetics of Digoxin: 
Results of Double-Blind, Placebo-Controlled, 
Parallel-Group Study 
D. Kleinermans ’, SJ. Brown *, S.A. Willavize *. L. Purkins 
‘Dfiar  Central Research, Sandwich, UK, 2pf;..  Central Research, 
Groton, USA 
Digoxin has a narrow therapeutic index and is potentially toxic. A 
study was performed to establish if multiple doses of mvafloxacin 
have any effect on the steady-state pharmacokinetics of ckgoxin. 
Digoxin was taken by 16 healthy male volunteers &om day 1 to 
20. In addition, on days 11-20, volunteers were randomized to re- 
ceive trovafloxacin (200 mg once daily) or placebo at the same time 
as digoxin was taken. Throughout the study, 12-lead ECGs, blood 
pressure and pulse rate were monitored. O n  days 10 and 20, blood 
samples were obtained at intervals over a 24-h period and complete 
urine collections were made. D i g o ~  concentrations in plasma and 
urine were determined by rackoimmunoassay Digoxin pharmacoki- 
netic parameters on days 10 and 20 were as follows. 
Day 10 before mamcntwith Day 20 after mament wifh 
Parameter Trovafloucin Placebo Tmfloxlcin Phccbo 
AUC? (ng.h/ml) 16.5 1 5.4 15.6 13.2 
Cmu (Wd) 2.0 1.9 2.2 1.6 
CLR (ml/min) 153.4 156.2 154.4 143.2 
T m  01) 1.2 1.1 0.8 1.1 
There was no statistically sipficant differences, as measured by 
the ditference between day 20 and day 10 in AUCt, for the two 
treatment groups. Similarly, there was no ditference in C1R of 
digoxin when trovafloxacin was administered. It is concluded that 
multiple doses of trodoxacin have no effect on steady-state serum 
concentrations of digoxin. 
(p3851 An Open, Placebocontrolled, Two-way 
Crossover Study to Investigate the Effects of 
Cimetidine on the Steady-state 
Pharmacokinetics of Trovafloxacin 
L. Purkins S.D. Oliver ’, S.A. Willavize 3 .  ’ Dfizer Central Research, 
Sandwich, UK, ’Besselaar, Lee& UK, ’pf;, Central Research, Groton, 
USA 
Cimetidme’s ability to inhibit Phase I P-450-mediated metabolic 
reactions, renal tubular secretion and gastric acid secretion results 
in decreased metabolism, renal clearance and absorption of some 
drugs. Pharmacokinetic drug interactions have been reported for 
the fluoroquinolones enoxacin, temafloxacin and ofloxacin during 
concomitant theram. 
Healthy male volunteers (n = 12) were randomized to receive ei- 
ther cimetidme (400 mg twice daily) or placebo for 2 days. On days 
3-5, the volunteers received the new fluoroquinolone trodoxacin 
(200 mg once daily) as well as cimetidine or placebo. After a min- 
imum of 7 days’ washout, the study was repeated with those vol- 
unteers who received placebo during the first study period being 
treated with cimetidine, and vice versa. 
Multiple dosing with cimetidine compared with placebo did not 
have any statistically sigdcant effects on the following steady-state 
pharmacokmetic parameters of trovafloxacin: C,, (placebo 2.5 
pg/ml, cimetidme 2.4 pg/ml); T,, (placebo 1.5 h, cimetidine 1.4 
h); AUC* (placebo 27.1 figh/ml, cimetidine 27.8 pgh/ml). 
It is concluded that cimetidine does not have any clinically sig- 
ruficant effect on the systemic exposure to trodoxacin following 
multiple oral dosing. This reflects the facts that mdoxac in  is elim- 
inated by conjugation and that renal clearance of the unchanged 
drug is low. 
(p3861 BAY 12-8039 (6): Study on the Food Effect after 
Oral Administration of 200 mg SD to Healthy 
Volunteers 
H. S d ,  A. Dalhoff, D. Kubitza. Bayer AG, Wuppertal, Pharma 
Research C e n t q  F R G  
Objectives: To asses safety, tolerability and the d u e n c e  of an 
American breakfast (AB) on the pharmacokmetics (F‘K) of B. To 
evaluate the effect on antimicrobial activity (AA) using PK/PD mod- 
e h g  based on in vitro bactericidal kinetic experiments. 
Methods: In an open, randomised crossover study 6 male sub- 
jects received a 200 mg oral dose of B with and without an AB. 
Plasma concentrations were determined by HPLC, compartmental 
and non-compartmental PK-parameten were calculated. To evaluate 
the influence of a food effect on AA PK/PD modekng was done 
based on in vim lulling experiments using Strep Pneumonia mimic- 
ing human PK. PK were fitted to a 2 compartment model, a sipnoid 
E, model was used to describe the killing kinetics. The resulting 
PK/PD model was applied to the study data to predict changes in 
AA induced by food. These results were compared to data from 
calculation of endpoints like AUC/MIC or C,/MIC. 
Results: Extent of absorption was not influenced by food (AUC: 
15.0 mg*h/l). Peak concentrations were 16% decreased by an AB 
(1.04 vs. 1.22 mg/l), t,- was prolonged (3.6 vs. 1.4 h) inckcating 
influence of food on absorption rate. B was well tolerated in the 
study. In vitro AA was not influenced by the food effect. Both 
methods of PK/PD correlation yielded comparable results, however, 
breakthrough calculations were less consistent. 
Conclusions: Food has no clincally relevant effect on the kinetics 
of B in humans. 
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LP387 Phannacokinetics (PK), Safety (S) and 
Tolerability (T) of 600 mg BAY 12-8039 (BA) 
Administered Once Daily over 10 Days 
H. S d ,  U. Schuldy, W. Wingender. Pharma Research Center, Bayer 
A G ,  Wupperial, Germany 
Objectives: To assess S,  T, and PK of 600 mg BA admmistered 
orally to 7 healthy male volunteers over 10 days. 
Methods: In a double blind, randomized, placebo controlled, 
parallel group comparison 10 healthy male volunteers received a 
600 mg BA (N = 7) or placebo (N = 3) once daily over 10 
days. On day 1 and 10 of treatment plasma and urine concentra- 
tions were determined by specific HPLC with an LOQ of 5 pg/l. 
Non-compartmental PK parameters were determined and compared 
to data obtained in previous studies. S and T investigation included 
ECG, vital signs, adverse events and clinical laboratory (clin. chem- 
isny, hematology, urdysis).  
Results: The study drug was well tolerated with no relevant 
changes of vital signs, ECG and laboratory parameters. Peak con- 
centrations of 4.7 (4.6-7.2) mgA were reached 0.5-2.5 h p.a. (tmur) 
in the steady state, trough (24 h) concentrations were 1.0 (0.6-1.4) 
mg/l. The AUC increase from 50 (32-66) mg*h/l at day 1 to 60 
(42-78) mg*h/l on day 10 was accompanied by a slightly decreased 
Cl,, at steady state (2.4 M 3.3 l/h after 1" dose). Variability of PK 
was unchanged. The data were in good accordance with previous 
studies. 
Conclusions: Due to the excellent S,  T and the favorable PK 
(long tl/2, fast distribuaon) BA is an  excellent drug candidate for 
RTI to be dosed OD up to 600 mg. The sllght deviation form 
linearity in PK at steady state is not of clinical relevance. 
Ip3881 Phannacokinetics (PK), Safety (S) and 
Tolerability (T) of 800 mg BAY 12-8039 (BA) 
Administered Orally as a Single Dose 
H. StaB, D. Kubitza, U. Schiihly, 
Center, Bayer AG, Wupperfal, Germany 
Objectives: To assess S, T, and PK of 800 mg BA administered 
orally to 7 healthy male volunteers 
Methods: In a double blind, randomized, placebo controlled, 
crossover study 7 healthy male volunteers received a single dose 
of 800 mg BA or placebo on 2 occasions separated by a washout 
period of 1 week. Plasma and urine concentrations were deter- 
mined by vhdated HPLC with an LOQ of 5 pg/l up to 96 h 
p.a. Non-compartmental PK parameters were determined and com- 
pared to data obtained in previous studies with doses ranging be- 
tween 50-600 mg SD. S and T investigation induded ECG, EEG, 
vital signs, adverse events and clinical. lab (din. chemisny, hematol- 
ogy, urinalysis). 
Results: The study drug was well tolerated with no relevant 
changes of vital signs, ECG, EEG or laboratory parameters. The PK 
data were in accordance with results h m  earlier studies, variability 
was low. Peak concentrations of4.7 (4.0-5.6) mgA were reached 2-4 
h p.a. (hu). AUC was 60 (42-78) mg*h/l. t1/2 of ca. 15 h described 
elimination of the drug. 
Conclusions: PK of single BA doses administered orally are linear 
up to 800 mg. Due to the excellent S ,  T and the favorable PK (long 
t1/2, fast distribution) BA is an excellent drug candidate for RTI to 
be dosed OD. 
Wingender. Pharma Research 
I P389 [ Pharmacokinetics (PK) and Tolerability of the 
New Quinolone BAY 12-8039: 10 Days Treatment 
at 400 mg Daily 
J.T. Sull~van, M. Woodruff, J. Lettieri, V. Agarwal, G. Krol, 
A. Heller. Bayer Corporation, West Haven CT USA 
Objectives: To determine PK and safety of 10 days of oral treat- 
ment with 400 mg BAY 12-8039, and to project pharmacodynamic 
response. 
Methods: Healthy volunteers received either BAY 12-8039 (7 
M, 3 F) or placebo (3 M, 2 F) once daily for 10 days. PK plasma 
profiles (by HPLC) were completed on Days 1 and 10. Derived 
AUIC (AUC/MIC) values (MIC for strep. pneum. = 0.25 mg/l), 
and Cmax/MIC ratios were calculated for Days 1 and 10. Hema- 
tology, blood chemistry, vital signs, ECG, and adverse events were 
monitored at appropriate intervals. 
Results: PK parameters (geometric meanlgsd) and AUIC, 
Cmax/MIC values were: 
Day 1 Day 10 
AUC (mg h/l) 30.2/ 1.15 48.0) 1.06 
AUCnorm (kg h/l) 5.7/1.11 9.0/1.18 
3.3/ 1.24 4.511.13 Cmax (mg/l) 
r1/2 (h) 9.3/1.13 12.7/1.17 
AUIC (h) 121 192 (target values > 125) 
Cmax/MIC 13.2 18 (target d u e s  >lo)  
Plasma concentrations exceeded MIC throughout the dosing in- 
terval. There were no chcally relevant changes in vital sips, hema- 
tology, blood chemistry or ECG. Adverse events were not signifi- 
cantly Werent between drug and placebo conditions. Nausea was 
reported more hquently with BAY 12-8039. 
Conclusions: PK parameters are consistent with linear kinetics. 
Based on these data a daily dose of 400 mg was well tolerated and is 
expected to be sufficient to treat Strep. pneumo. infecnons. 
Amoxicillin (AMX) Versus Cefotaxime (CTX) 
Ex-Vivo Antibacterial Activity Against 
Penicillin-Susceptible (PSP) and Penicillin- 
Resistant (PRP) Skeptococcus pneumoniae 
Strains 
L. Aguilar ' , M. Martin ', A. Carcas ', 1.P Balcabao ', P. Guerra 3 ,  
J. Frias ', M. G6mez-Lus ', M.J. Gimenez I ,  R. Dal-Re ', 
J. Prieto '. 'SmithMine Beecham Pharmaceuticals, Madrid, 'Universidad 
Complutense, Madrid, Universidad Autonoma, Madrid, Spain 
A randomized, cross-over phase I study with 875 mg oral AMX and 
1 g IM CTX single doses was carried out in 12 healthy volunteers 
with a 7-day washout period. Serum samples were collected at 
0, 15 min, 30 min, 1, 1.5, 2, 4, 6 and 8 h after dosing. Levels 
were measured by bioassay. Serum bactericidal t iws (SBTs) were 
measured by standard NCCLS methods using Todd-Hewitt broth 
with 80% volunteer antibiotic-free serum obtained fiom each 
volunteer prior to dosing, as sample diluent. Therapeutic index 
(TI = Peak level/MIC) and Area under inhibitory curve (AUIC 
= AUC/MIC), were calculated. Area under bactericidal curve 
MIC/MBC PSP PRP 
CTX AMOX CTX W d  AMOX 
0.01/0.01 0.01/0.01 1/2 112 
TI 857 f 149' 2711 166' 8.6 f 1.5' 27.1 k 1.7' 
AUIC 3543 f 692' 8342 f 1531. 35.4 6.9' 83.4 f 15.3' 
AUBC 1461 f 554 1304 k 219 24.7 f 11.8 22.4 f 5.1 
* P  < 0.002 AMOX VI CTX 
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(AUBC) were obtained f b m  SBTs using the trapezoidal rule. Data 
(mean f SD) are shown in the table. 
Similar experimental ex-vivo anti-pneumococd activity (AUBC) 
against PFW or PSP was obtained with both AMX and CTX despite 
the higher statistically sipficant calculated pharmacodynarmc d u e s  
for CTX, (3 times for TI and 2.5 for AUIC) or the use .of the oral 
route for AMX and the IM for CTX. 
the tissu and the dose and the regimen. However, ifMIC is 4 mgA 
the T > MIC re& at 100% only for GIII, falling to 87.5% in 
plasma and 43.8% in BM for GI, while it stays always under MIC in 
L for GII. 
Conclusions: When using the same doselday, the CI does not 
impair the diffusion of CEF in the LRT by comparison with ID, 
provides a PK profile able to optimize the CEF pharmacodynamics, 
according to its time dependent bactericidal activity. 
I P391 I Penetration of Cefuroxime into Middle Ear 
Effusion after a Single Dose of Cefuroxime 
Axetil in Patients with Acute Otitis Media 
E. Thoroddsen ' , C. Marr * . ' The Medical Clinic, Reykjavik, Iceland, 
'Glaxo Welkome RGD, Middlesex, UK 
Objectives: To study the penetration of cefuroxime into middle 
ear efhsion (MEE) and serum concentration after a single oral dose 
of cefuroxime axetil, to relate the cefurolcime concentrations to the 
mmimum uhbitory concentration (MIC) of key pathogens and to 
calculate the time above MIC in relation to the dosing interval. 
Methods: In this open, single-centre study, 26 paedntric patients 
with acute otitis media were enrolled. Serum and MEE samples 
were taken between 2 and 5 hours after oral dosing of 15 mg/kg 
cefuroldme axedl to children after food. Cefuroxime concentrations 
were analysed by liquid chromatography-mass spectrometry assv. 
Results: Serum concentrations of cefuroxime ranged f b m  2.8 
to 7.3 pg/mL being above the MIGO value (2 pg/mL) for 
key pathogens associated with acute otitis media (includmg peni- 
cillin-susceptible and intermediately-resistant Streptococcus pneumo- 
niae and fi-lactamase-producing strains of Haemophilus injuenzae and 
Moraxella utanhalir) for at least 42% of the 12-hour dosing interval. 
Concentrations of cefuroxime were detected in 14/17 (82%) MEE 
samples and ranged fbm 0.2 to 3.6 pg/mL.. 
Conclusions: Cefimxime is well absorbed and penetrates well 
into MEE after oral dosing. The time for which the serum con- 
centration of cefuroxime remained above the MICw values for the 
key pathogens suggests that cefuroxime axed 15 mg/kg bid should 
eradmte bacterial pathogens and effectively treat acute otitis media 
in children. 
I P392 I Phannacokinetics (PK) of Ceftazidime (CEF) in 
Plasma, Bronchial Mucosa (BM) and Lung (L) of 
Rabbits after Continuous Infusion (Cl) versus 
Intermittent Dosing (ID) 
R. G d o ,  L. Rigaudy. Patteur Hospital, Unix $Nice and 
Gho- Wellcome ,Laboratory, Paris, France 
Objectives: To compare the PK and PD profiles of CEF in plasma 
and in the low respiratory tract &RT) after ID or CI admmistration. 
Methods: The concentrations of CEF in plasma, BM and L were 
determined at steady-state in 3 groups of 15 rabbits each. They 
received either a 33.3 mg/kg by ID every 2.75 h (GI), or a 33 mg/kg 
loading dose followed by 50 mg/kg as a 8.25 h CI (GII), or a 33 
mg/kg loading dose and 100 mg/kg by CI (GIII) reproducing thus 
the human dosage regimens of respectivelly 2 g/8 h, 3 g/24 h and 6 
g/24 h. Then the period of time that plasma or tissu concentrations 
exceed the MIC were calculated for each study group considering 2 
MICs dues ,  i.e. 0.5 and 4 mgA. 
Results: The PK parameters calculated for plasma, BM and L are 
as follow: T1/2 = 0.68, 1.28 and 0.92 h the AUCs = 305 pgh/ml, 
165.5 and 39.2 pgh/g  (GI), 173.6 pgh/ml, 63.9 and 26 pgh/g  
(GII), 349.4 pgh/ml, 172.2 and 58.2 pgh/g  (GIII). Considering a 
bacteria with a MIC 90 of 0.5 mgA it appears that the period of time 
that CEF concentrations exceed MIC (T > MIC) is 100% whatever 
1 P393 I Stability of Meropenem in a Portable Pump 
Resewoir 
R.A.A. Math&, A.I. de G d ,  A.A.T.M.M. Vinkr. Lnboratory $ 
Clinical Pharmacology and T'icolon, The Hague Hospitals Central 
Pharmq,  The Hague, The Netherlands 
Objectives: To assess the stabihty of meropencm in a portable pump 
reservoir used for home intravenous antibiotic treatment during stor- 
age at -20 and +5"C and in vim continuous infusion at 20,25 and 
30°C. 
Methods: For each temperature three 100 ml polyvinyl chloride 
(PVC) reservoirs were fded with a solution of meropenem (as the 
sodium Sat) in water for injection; concentrations were 50 mg/ml 
in vitro delivery serial samples were taken at regular intends over a 
period of 0-140 days (-20°C), 0-21 days (+5"C) and 0-24 hours 
(20, 25, 30'C). The solutions were inspected for visual changes 
and drug concentrations were determined by a stability-indicating 
high-peIformance liquid chromatographic procedure. The delivered 
dose was calculated by using the area under the concentration-time 
curve. 
Results: Meropenem solutions were stable (no more than a 10% 
reduction fbm initial concentration and no detectable change in 
solution colour and clarity) for 28 days and 24 hours when stored at 
-20°C and +5OC, respectively (p <0.05). During constant lnfusion 
solutions were stable for up to 8, 9 and 6 hours at 20, 25 and 
30"C, respectively (p t0.05). It was calculated that during 12 hours 
of continuous lnfusion more than 90% of the nominal dose was 
delivered at the investigated temperatures (p ~0.05). 
Conclusions: The results of this study demonstrate that 
meropenem can be used in home intravenous antibiotic treatment. 
The portable pump reservoirs can be stored in the patient's hezer 
(-20'C) for the course of the theram. After thawing under re- 
fkigeration (+5"C) meropenem can be administered by continuous 
infusion during 12 hours. 
(-20, +5OC) and 30 mg/d (20, 25, 30°C). D u ~ g  s t o w  and 
Oral Tissue Transfer of S-1090. a New Oral 
Cephalospolins, in Rabbit Infection Models 
T. Satoh, H. H o h o ,  M. Yamaguchi, T. Mi+, M. Ohmura. 
The Nippon Dental University, Tokyo, Japan 
Objectives: A newly developed nonestrified oral cephalosporins, 
S-1090, is expected to have beneficial effem on oral infections. We 
experimentally prepared rabbit models with mandibular infection 
and performed single administration of S-1090 in order to study its 
oral tissue transfer f b m  the aspect of pharmacokinetics. 
Methods: The animals used were male NZW rabbits weighmg 
2.5-3 kg Rabbit models with mandibular infection were prepared 
by inoculating Streptococcu millm' (NCTC 7331) and h o i d a j a g -  
ilk (NCTC 9343) into their mandibles. Carboxymethyl cellulose 
(0.5%) w a s  mixed with S-1090 and the mixture was administered in 
a dose of 5 mg/kg to the anunals while fasting. The animal mod- 
els were observed for 720 minutes after the completion of s-1090 
administration. During the observation period, blood samples were 
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collected nine times and oral tissues (tongue, gingiva, submandibular 
lymph node, parotid gland, submandihular gland, mandible) samples 
were collected nine times. The transfer concentration of S-1090 was 
determined by the paper disc method of bioassay using Prm'den- 
cia stuartii (IF0 12930) as the test bacterium and pharmcokinetic 
analysis was carried out. 
Results: Laboratory findings of serum samples were as follows: 
Tmax (1.95 h), Cmax (11.22 pg/ml), AUC (82.52 ,ugh/&) and 
those of tissue samples included the following: Tmax (2.64-4.35 h), 
Cmax (1.62-3.56 pg/g), AUC (22.81-42.72 pgh/g). 
Conclusion: The transfer levels of S-1090 were significantly high 
in the oral tissues including parotid gland and gingiva. 
I P395 I Pharmacodynamic Evaluation of New 
Glycopeptides Using In Viro Models of 
Infection against Methicillin-Resistant 
Staphylococcus aureus (MRSA) 
R.-C. Mercier, M.L. Rybak. The Anti-Infective Research LzboratoT, 
Wayne State University and Detroit Receiving Hospital, Detroit, MI, 
U S A  
Objectives: LY333328 (LY28) and LY191145 (LY45) are two in- 
vestigational glycopeptides which have been shown to have good 
activity against resistant strains of Staphylococcus aureus. We compared 
the activity of LY28, LY45 and vancomycin (V) against one clinical 
strain of MRSA. 
Methods: Three Merent in vim models were used a simulated 
endocardial vegetation (SEV) model, an abscess model (AM) and a 
bacteremic model (BM). A starting inocdum of -lo9 CFU/g was 
used for the SEV model and inocula of--1O6 CFU/rnl were used for 
the AM and BM. The LY compounds were tested in the presence 
or abscence of albumin (Alb, 4 g/dL). Bacterial densities at 48 or 72 
h were compared between regimens. 
Results: MICs/MBCs of the MRSA were LY28: 1/2, LY45: 
0.125/0.25 and V 0.5/1 pg/ml. 
Aloglo CFU/ml or g @ 72 h 
SEV Model Abscess Model Bicteremic model 
A loglo C N / d  @ 48 h 
Regmcn Peakconc. Alh No Alh Peakconc. No Alb Peakconc. Alb No Alb 
( W L )  ( m g 4  (mgW 
LY28 12 +1.4 8 +3.3 40 -3.8 
LY45 12 -0.3 8 -0.9 40 -4.0 
V 30 -2.0 30 -4.1 30 +3.2 
Growrh Connol +0.9 +3.2 +2.8 
30 +1.5 40 -0.7 
30 -0.8 40 -3.6 
Conclusions: In the SEV model, no killing was observed with 
LY28; LY45 and V were sipficandy better than LY28. Sipficant 
binding of the LY compounds to the membrane may occur in the 
AM which could explain the decrease in activity. Structure-activity 
relationship may also be responsible for the Werence between the 
three glycopeptides. 
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lp3961 The in vitm Activity of Trovafloxacine, 
Ciprofloxacine and lmipenem against Clinical 
Isolates from the Intensive Care Units in Central 
Europe 
D. Dzierianowska , J. Patzer 
Memorial Health Institute, Wanatv, Poland, 'Regional Institute .f 
Hygiene, Ostrava, Czech Republic 
Objective: to compare the in-v+ro activity oftrovdoxacine (TFX), 
a new naphthyridone derivative of fluoroquinolone, with that of 
ciprofloxacin (CIP) and imipenem (IPM) against chical isolates 
f h m  the Intensive Care Unit. 
Materials and Methods: The kesh clinical consecutive isolates 
(n = 200) were obtained f h m  patients hospitalized in 1996. The 
Minimal Inhibitory Concentration (MIC) of TFX, CIP and IPM 
was determined by E-test. 
Results: TFX demonstrated greater activity against Sraphylococ- 
cus aureus (MIC90 2 mg/l) and Stapphylococcuc epidermidis 4 
mg/l) in comparison to CIP (MIC90 >32 mg/ml). TXF, CIP and 
IPM were characterized by the MIC9o < = 1 mg/l against all tested 
Gram-negative bacteria, with the exception of Stenotrophomonac mal- 
tophilia. TFX and CIP demonstrated identical activity against Meb- 
siella pneumoniae (MI& 0.75 mg/l) and nearly identical against En- 
terobacter cloacae (MIC90 0.04 mg/l or 0.032 mg/l). CIP was more 
active than TFX against Escherichia mli (MI& 0.23 mgA and 0.38 
mg/l, respectively). Pseudomonas aewginosa and Acinetobacter spp. had 
MIC9o >32 mg/l  for both TFX and CIP. 
Conclusion: TFX was the most active among tested antibiotics 
against clinical isolates of Staphylococcus aureus and Staphylococcus 
epidermidis. It had good activity against all tested isolates of Enter- 
obacteriaceae and 50% of l? aeruginosa. 
E. Chmelarova '. ' Children's 
Activity of Trovafloxacin Compared to 7 Other 
Agents Against 458 Gram-negative 
Nonfermenters 
M.A. Visalli I ,  M.R. Jacobs ', EC. Appelbaum I .  'Hershey Medical 
Center, Hershey, PA, U S A ,  ' C u e  Western Reserve University, 
Cleveland, OH, U S A  
Objectives: To test activity of trodoxacin compared to 
other quinolone and non-quinolone agents against Gram-negative 
non-fermenters. 
Methods: Agar dilution was used to test susceptibility of 
458 Gram-negative non-fermenters to mdoxac in ,  ciprofloxacin, 
ofloxacin, levofloxacin, spadoxacin, clindoxacin, ceftazidime, 
imipenem. 
Results: MIC~o/9os (pg/ml) are given in the table below. 
Conclusions: Trodoxacin yielded low MIC9os (14.0 pg/ml) 
against all common species except B. repacia, Alcaligenes and some 
acinetobacters. 
R ~1mx (89) 
EJuodpuf (13) 
B. qm (49) 
S mdto (82) 
Annets spp (52) 
C. m m q  (10) 
AU (458) 
A h l v  SPP (67) 
OW2.0 
1.0/8.0 
8.0/32.0 
1.0/2.0 
0.06/16.0 
16.0164.0 
1.0/4.0 
1/16 
0.25/4.0 
0.25/4.0 
8.0/32.0 
4.0A6.0 
0.5b256.0 
4.0l32.0 
2.0/8.0 
2/16 
2.0/4.0 
2.0116.0 
16.0/64.0 
4.0/8.0 
0.5/32.0 
8.0/32.0 
4.014.0 
2/32 
1.0/2.0 
1.0/8.0 
4.0/32.0 
1.0/2.0 
0.06/16.0 
4.0/32.0 
OW4.0 
1/16 
1.012.0 
1.0/8.0 
8.0/16.0 
2.0/4.0 
0.5/32.0 
4.0/32.0 
2.0/2.0 
1/16 
0.25/0.5 
0.25/2.0 
2.0/8.0 
0.5/2.0 
0.125/8.0 
0.5/8.0 
1.0/4.0 
OW4 
4.0/64.0 
4.0/64.0 
8.0/32.0 
64.01256.0 
8.0/64.0 
8.0/64.0 
128.0/>256.0 
8/128 
2.0 / 3 2.0 
2.0/256.0 
16.0/256.0 
256.0/256.0 
0.25/0.5 
1.0/8.0 
8.0/64.0 
2/256 
